Similar articles

• Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion.

  MacLeod RM, Lehmeyer JE. MacLeod RM, et al. Endocrinology. 1974 Apr;94(4):1077-85. doi: 10.1210/endo-94-4-1077. Endocrinology. 1974. PMID: 4818768 No abstract available.
• Effect of ergovaline, loline, and dopamine antagonists on rat pituitary cell prolactin release in vitro.

  Strickland JR, Cross DL, Birrenkott GP, Grimes LW. Strickland JR, et al. Am J Vet Res. 1994 May;55(5):716-21. Am J Vet Res. 1994. PMID: 8067623
• Effect of clozapine on dopamine-induced inhibition of prolactin release from cultured rat pituitary cells.

  Braghiroli L, Ponzianelli A, Fiani M, De Feo G, Cheng CY, Mazzanti G. Braghiroli L, et al. Pharmacol Res. 1997 Mar;35(3):173-5. doi: 10.1006/phrs.1996.0102. Pharmacol Res. 1997. PMID: 9229404
• Supersensitivity of pituitary dopamine receptors involved in the inhibition of prolactin secretion.

  Annunziato L, Quattrone A, Schettini G, Di Renzo G. Annunziato L, et al. Adv Biochem Psychopharmacol. 1980;24:379-85. Adv Biochem Psychopharmacol. 1980. PMID: 6105788 Review. No abstract available.
• Pharmacology of ergot alkaloids in clinical use.

  Berde B. Berde B. Med J Aust. 1978 Nov 4;2(3 Suppl):3-13. doi: 10.5694/j.1326-5377.1978.tb77379.x. Med J Aust. 1978. PMID: 370528 Review. No abstract available.